Alok A. Khorana, MD

Articles by Alok A. Khorana, MD

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

BySuneel D. Kamath, MD,Joanna Roopkumar, MD,Ying Ni, PhD,Minqian Shen, MD, PhD,Pablo Bejarano, MD,Daniela Allende, MD,Arun Nagarajan, MD,Tim Nguyen, MD,Bachar Dergham, MD,Dale Shepard, MD, PhD,Marc A. Shapiro, MD,Michael J. McNamara, MD,Bassam N. Estfan, MD,Kanika G. Nair, MD,Alok A. Khorana, MD

December 15th 2023

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors

ByMinhTri Nguyen, MD,Wei Wei, MS,Gregory Cooper, MD,Alok A. Khorana, MD,Suneel D. Kamath, MD

January 28th 2023

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

Latest Updated Articles

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors
Published: January 28th 2023 | Updated:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer
Published: December 15th 2023 | Updated:

Alok A. Khorana, MD

Articles by Alok A. Khorana, MD

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors

Latest Updated Articles

Trending on CancerNetwork

CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC